Global Anti-Obesity Therapeutics Market By Type (Polyethylene Powder Coating, Polypropylene Powder Coating, Pvc Powder Coating, Polypropylene Powder Coating, Polyphenylene Sulfide Powder Coating, And Others), By Application (Medical Appliances, Food Processing Industry, Aviation, Railroad, And Automotive), By Region And Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends And Forecast 2019-2028
- Published date: Oct 2021
- Report ID: 13653
- Number of Pages: 359
- Format:
- keyboard_arrow_up
- 1. Anti-Obesity Therapeutics Market Introduction
- 1.1. Definition
- 1.2. Taxonomy
- 1.3. Research Scope
- 2. Executive Summary
- 2.1. Key Findings by Major Segments
- 2.2. Top strategies by Major Players
- 3. Global Anti-Obesity Therapeutics Market Overview
- 3.1. Anti-Obesity Therapeutics Market Dynamics
- 3.1.1. Drivers
- 3.1.2. Opportunities
- 3.1.3. Restraints
- 3.1.4. Challenges
- 3.2. PESTLE Analysis
- 3.3. Opportunity Map Analysis
- 3.4. PORTER'S Five Forces Analysis
- 3.5. Market Competition Scenario Analysis
- 3.6. Product Life Cycle Analysis
- 3.7. Opportunity Orbits
- 3.8. Manufacturer Intensity Map
- 3.1. Anti-Obesity Therapeutics Market Dynamics
- 4. Global Anti-Obesity Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Type, 2012-2028
- 4.1. Global Anti-Obesity Therapeutics Market Analysis by Type: Introduction
- 4.2. Market Size and Forecast by Region
- 4.3. Centrally Acting Anti-obesity Drugs
- 4.4. Peripherally Acting Anti-obesity Drugs
- 5. Global Anti-Obesity Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Application, 2012-2028
- 5.1. Global Anti-Obesity Therapeutics Market Analysis by Application: Introduction
- 5.2. Market Size and Forecast by Region
- 5.3. Hospital Use
- 5.4. Clinic Use
- 5.5. Household
- 5.6. Other
- 6. Global Anti-Obesity Therapeutics Market Value ((US$ Mn)), Share (%), and Growth Rate (%) Comparison by Region, 2012-2028
- 6.1. North America
- 6.1.1. North America Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.1.1.1. US
- 6.1.1.2. Canada
- 6.1.1.3. Mexico
- 6.1.1. North America Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.2.1. Europe
- 6.2.1. Europe Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.2.1.1. Germany
- 6.2.1.2. France
- 6.2.1.3. UK
- 6.2.1.4. Russia
- 6.2.1.5. Italy
- 6.2.1.6. Spain
- 6.2.1.7. Rest of Europe
- 6.2.1. Europe Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.3. Asia-Pacific
- 6.3.1. Asia-Pacific Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.3.1.1. China
- 6.3.1.2. Japan
- 6.3.1.3. Korea
- 6.3.1.4. India
- 6.3.1.5. Rest of Asia
- 6.3.1. Asia-Pacific Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.4. Latin America
- 6.4.1. Latin America Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.4.1.1. Brazil
- 6.4.1.2. Argentina
- 6.4.1.3. Rest of Latin America
- 6.4.1. Latin America Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.5. Middle East and Africa
- 6.5.1. Middle East and Africa Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.5.1.1. GCC
- 6.5.1.2. South Africa
- 6.5.1.3. Israel
- 6.5.1.4. Rest of MEA
- 6.5.1. Middle East and Africa Anti-Obesity Therapeutics Market: Regional Trend Analysis
- 6.1. North America
- 7. Global Anti-Obesity Therapeutics Market Competitive Landscape, Market Share Analysis, and Company Profiles
- 7.1. Market Share Analysis
- 7.2. Company Profiles
- 7.3. Bristol-Myers Squibb
- 7.3.1. Company Overview
- 7.3.2. Financial Highlights
- 7.3.3. Product Portfolio
- 7.3.4. SWOT Analysis
- 7.3.5. Key Strategies and Developments
- 7.4. Eisai Company
- 7.4.1. Company Overview
- 7.4.2. Financial Highlights
- 7.4.3. Product Portfolio
- 7.4.4. SWOT Analysis
- 7.4.5. Key Strategies and Developments
- 7.5. FlaxoSithKline plc.
- 7.5.1. Company Overview
- 7.5.2. Financial Highlights
- 7.5.3. Product Portfolio
- 7.5.4. SWOT Analysis
- 7.5.5. Key Strategies and Developments
- 7.6. Novo Nordisk
- 7.6.1. Company Overview
- 7.6.2. Financial Highlights
- 7.6.3. Product Portfolio
- 7.6.4. SWOT Analysis
- 7.6.5. Key Strategies and Developments
- 7.7. Alizyme
- 7.7.1. Company Overview
- 7.7.2. Financial Highlights
- 7.7.3. Product Portfolio
- 7.7.4. SWOT Analysis
- 7.7.5. Key Strategies and Developments
- 7.8. BoehringerIngelheim GmbH
- 7.8.1. Company Overview
- 7.8.2. Financial Highlights
- 7.8.3. Product Portfolio
- 7.8.4. SWOT Analysis
- 7.8.5. Key Strategies and Developments
- 7.9. Pfizer
- 7.9.1. Company Overview
- 7.9.2. Financial Highlights
- 7.9.3. Product Portfolio
- 7.9.4. SWOT Analysis
- 7.9.5. Key Strategies and Developments
- 7.10. Takeda Pharmaceutical
- 7.10.1. Company Overview
- 7.10.2. Financial Highlights
- 7.10.3. Product Portfolio
- 7.10.4. SWOT Analysis
- 7.10.5. Key Strategies and Developments
- 7.11. Rhythm Pharmaceuticals
- 7.11.1. Company Overview
- 7.11.2. Financial Highlights
- 7.11.3. Product Portfolio
- 7.11.4. SWOT Analysis
- 7.11.5. Key Strategies and Developments
- 7.12. Shionogi USA
- 7.12.1. Company Overview
- 7.12.2. Financial Highlights
- 7.12.3. Product Portfolio
- 7.12.4. SWOT Analysis
- 7.12.5. Key Strategies and Developments
- 7.13. Vivus
- 7.13.1. Company Overview
- 7.13.2. Financial Highlights
- 7.13.3. Product Portfolio
- 7.13.4. SWOT Analysis
- 7.13.5. Key Strategies and Developments
- 7.14. Zafgen
- 7.14.1. Company Overview
- 7.14.2. Financial Highlights
- 7.14.3. Product Portfolio
- 7.14.4. SWOT Analysis
- 7.14.5. Key Strategies and Developments
- 7.15. Norgine Pharmaceuticals Ltd.
- 7.15.1. Company Overview
- 7.15.2. Financial Highlights
- 7.15.3. Product Portfolio
- 7.15.4. SWOT Analysis
- 7.15.5. Key Strategies and Developments
- 8. Assumptions and Acronyms
- 9. Research Methodology
- 10. Contact
- 1. Anti-Obesity Therapeutics Market Introduction
- Bristol-Myers Squibb
- Eisai Company
- FlaxoSithKline plc.
- Novo Nordisk A/S Company Profile
- Alizyme
- BoehringerIngelheim GmbH
- Pfizer Inc Company Profile
- Takeda Pharmaceutical
- Rhythm Pharmaceuticals
- Shionogi USA
- Vivus
- Zafgen
- Norgine Pharmaceuticals Ltd.
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |